Castle Biosciences INC: management transactions · United States · SEC (Form 4)

About Castle Biosciences INC

Castle Biosciences, Inc. (NASDAQ: CSTL) is a U.S.-based molecular diagnostics company headquartered in Friendswood, Texas, in the United States. For French-speaking investors, it is a healthcare specialist focused on prognostic and diagnostic tests designed to improve treatment decisions in areas with meaningful unmet medical need. The company was founded in 2007 by Derek Maetzold, who remains its President and Chief Executive Officer. Its business model is built around proprietary laboratory-developed tests that aim to deliver clinically actionable information derived from tumor biology and related molecular signatures. Castle’s legacy and still-core franchise is dermatologic oncology. Its portfolio includes DecisionDx-Melanoma, DecisionDx-SCC, and MyPath Melanoma, which are intended to help clinicians refine risk assessment for patients with cutaneous melanoma, cutaneous squamous cell carcinoma, and suspicious pigmented lesions. The company has also expanded beyond skin cancer into gastroenterology through TissueCypher, a test used to identify Barrett’s esophagus patients at higher risk of progression to esophageal cancer. More recently, Castle launched AdvanceAD-Tx to support systemic treatment decision-making in moderate-to-severe atopic dermatitis, underscoring a strategy of broadening its franchise into adjacent high-value disease areas. From a competitive standpoint, Castle positions itself as a focused specialist in high-utility molecular testing, differentiated by clinical evidence and physician adoption rather than scale alone. The company emphasizes a substantial body of peer-reviewed publications and accumulating real-world data that support the clinical validity and utility of its tests versus conventional pathology or staging approaches. Operationally, its footprint remains U.S.-centric, with clinical laboratories in Phoenix and Pittsburgh alongside its new corporate headquarters in Friendswood. That setup supports both commercialization and laboratory execution while keeping the company close to U.S. clinicians and payer dynamics. Recent developments highlight improving momentum. In the first quarter of 2026, Castle reported revenue of $83.7 million and raised full-year 2026 revenue guidance to $345–355 million, reflecting strong performance from its core growth drivers, DecisionDx-Melanoma and TissueCypher. The company also announced the grand opening of its new headquarters in Friendswood in March 2026, a sign of long-term investment in infrastructure and capacity. For investors, CSTL offers exposure to a NASDAQ-listed U.S. diagnostics platform with specialized growth franchises, but it also carries the usual risks tied to reimbursement, regulatory scrutiny, and the need to continually prove clinical and economic value.